trending Market Intelligence /marketintelligence/en/news-insights/trending/9H7WAzS08AI9XYF8fquThA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Anthera's kidney disease drug gets FDA orphan designation

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Anthera's kidney disease drug gets FDA orphan designation

The U.S. Food and Drug Administration granted orphan drug designation to Anthera Pharmaceuticals Inc.'s blisibimod for the treatment of immunoglobulin A nephropathy.

Blisibimod targets B-cell activating factor, which has been shown to be elevated in various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, immunoglobulin A nephropathy and others.

Immunoglobulin A nephropathy, also known as Berger's disease is characterized by deposition of immune complexes in the kidney, resulting in inflammation, the leakage of blood and protein into the urine, and loss of kidney function.